相似文献
1
Identification of New Small-Molecule Inducers of Estrogen-related Receptor α (ERRα) Degradation.
ACS Med Chem Lett. 2019 Apr 12;10(5):767-772. doi: 10.1021/acsmedchemlett.9b00025. eCollection 2019 May 9.
2
Discovery of potent epidermal growth factor receptor (EGFR) degraders by proteolysis targeting chimera (PROTAC).
Eur J Med Chem. 2020 Mar 1;189:112061. doi: 10.1016/j.ejmech.2020.112061. Epub 2020 Jan 14.
3
Exploring the PROTAC degron candidates: OBHSA with different side chains as novel selective estrogen receptor degraders (SERDs).
Eur J Med Chem. 2019 Jun 15;172:48-61. doi: 10.1016/j.ejmech.2019.03.058. Epub 2019 Mar 26.
4
Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer.
Eur J Pharmacol. 2016 Oct 15;789:439-448. doi: 10.1016/j.ejphar.2016.08.008. Epub 2016 Aug 4.
5
Regulation of PPARgamma coactivator 1alpha (PGC-1alpha) signaling by an estrogen-related receptor alpha (ERRalpha) ligand.
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):8912-7. doi: 10.1073/pnas.0401420101. Epub 2004 Jun 7.
6
Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal (BET) proteins - A review.
Drug Discov Today Technol. 2019 Apr;31:43-51. doi: 10.1016/j.ddtec.2019.04.001. Epub 2019 May 1.
7
Estrogen-related receptor alpha in human breast carcinoma as a potent prognostic factor.
Cancer Res. 2004 Jul 1;64(13):4670-6. doi: 10.1158/0008-5472.CAN-04-0250.
8
Estrogen-related receptor alpha is critical for the growth of estrogen receptor-negative breast cancer.
Cancer Res. 2008 Nov 1;68(21):8805-12. doi: 10.1158/0008-5472.CAN-08-1594.
9
MicroRNA-497 downregulation contributes to cell proliferation, migration, and invasion of estrogen receptor alpha negative breast cancer by targeting estrogen-related receptor alpha.
Tumour Biol. 2016 Oct;37(10):13205-13214. doi: 10.1007/s13277-016-5200-1. Epub 2016 Jul 25.
10
Function of estrogen-related receptor alpha in human endometrial cancer.
J Clin Endocrinol Metab. 2006 Apr;91(4):1573-7. doi: 10.1210/jc.2005-1990. Epub 2006 Feb 7.
引用本文的文献
1
Unraveling the secrets of novel PROTACs to improve degradation efficacy.
Mol Divers. 2025 Jul 5. doi: 10.1007/s11030-025-11273-9.
2
Investigating protein degradability through site-specific ubiquitin ligase recruitment.
RSC Chem Biol. 2024 Dec 13;6(2):240-248. doi: 10.1039/d4cb00273c. eCollection 2025 Feb 5.
3
Covalent Proximity Inducers.
Chem Rev. 2025 Jan 8;125(1):326-368. doi: 10.1021/acs.chemrev.4c00570. Epub 2024 Dec 18.
4
Investigating Protein Degradability through Site-Specific Ubiquitin Ligase Recruitment.
bioRxiv. 2024 Nov 12:2024.11.11.623099. doi: 10.1101/2024.11.11.623099.
5
Targeted protein degradation: advances in drug discovery and clinical practice.
Signal Transduct Target Ther. 2024 Nov 6;9(1):308. doi: 10.1038/s41392-024-02004-x.
6
International Union of Basic and Clinical Pharmacology CXIII: Nuclear Receptor Superfamily-Update 2023.
Pharmacol Rev. 2023 Nov;75(6):1233-1318. doi: 10.1124/pharmrev.121.000436. Epub 2023 Aug 16.
7
PROTAC'ing oncoproteins: targeted protein degradation for cancer therapy.
Mol Cancer. 2023 Mar 30;22(1):62. doi: 10.1186/s12943-022-01707-5.
8
Synthesis and Biological Evaluation of Novel Anti-leukemia Proteolysis-Targeting Chimeras in Degradating Inosine Monophosphate Dehydrogenase.
Iran J Pharm Res. 2022 Sep 10;21(1):e129251. doi: 10.5812/ijpr-129251. eCollection 2022 Dec.
9
Investigation into the Use of Encorafenib to Develop Potential PROTACs Directed against BRAF Protein.
Molecules. 2022 Dec 3;27(23):8513. doi: 10.3390/molecules27238513.
10
Quantitative Analysis and Optimization of Site-Specific Protein Bioconjugation in Mammalian Cells.
Bioconjug Chem. 2022 Dec 21;33(12):2361-2369. doi: 10.1021/acs.bioconjchem.2c00451. Epub 2022 Dec 2.
本文引用的文献
1
Plasticity in binding confers selectivity in ligand-induced protein degradation.
Nat Chem Biol. 2018 Jul;14(7):706-714. doi: 10.1038/s41589-018-0055-y. Epub 2018 Jun 11.
2
Indazole-based ligands for estrogen-related receptor α as potential anti-diabetic agents.
Eur J Med Chem. 2017 Sep 29;138:830-853. doi: 10.1016/j.ejmech.2017.07.015. Epub 2017 Jul 14.
3
The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.
Eur J Med Chem. 2017 Aug 18;136:457-467. doi: 10.1016/j.ejmech.2017.04.050. Epub 2017 Apr 22.
4
Targeted protein degradation by PROTACs.
Pharmacol Ther. 2017 Jun;174:138-144. doi: 10.1016/j.pharmthera.2017.02.027. Epub 2017 Feb 14.
5
Induced protein degradation: an emerging drug discovery paradigm.
Nat Rev Drug Discov. 2017 Feb;16(2):101-114. doi: 10.1038/nrd.2016.211. Epub 2016 Nov 25.
6
Characterization of a selective inverse agonist for estrogen related receptor α as a potential agent for breast cancer.
Eur J Pharmacol. 2016 Oct 15;789:439-448. doi: 10.1016/j.ejphar.2016.08.008. Epub 2016 Aug 4.
7
ERRα mediates metabolic adaptations driving lapatinib resistance in breast cancer.
Nat Commun. 2016 Jul 12;7:12156. doi: 10.1038/ncomms12156.
8
ERRα-Regulated Lactate Metabolism Contributes to Resistance to Targeted Therapies in Breast Cancer.
Cell Rep. 2016 Apr 12;15(2):323-35. doi: 10.1016/j.celrep.2016.03.026. Epub 2016 Mar 31.
9
Ligand Activation of ERRα by Cholesterol Mediates Statin and Bisphosphonate Effects.
Cell Metab. 2016 Mar 8;23(3):479-91. doi: 10.1016/j.cmet.2015.12.010. Epub 2016 Jan 14.
10
Modular PROTAC Design for the Degradation of Oncogenic BCR-ABL.
Angew Chem Int Ed Engl. 2016 Jan 11;55(2):807-10. doi: 10.1002/anie.201507634. Epub 2015 Nov 23.
Zotero 插件